Methods of treating, managing or preventing cutaneous lupus are disclosed. Specific methods encompass the administration of 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindol- e-1,3-dione alone or in combination with a second active agent. Pharmaceutical compositions and single unit dosage forms are also disclosed.